Stock Analiz

Lexaria Bioscience Corp. LEXX

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$4.44Market cap $9M
Open the interactive analysis →

Lexaria Bioscience Corp. (LEXX) is a healthcare company listed in the US with a market value of about $9M. In the twelve months to May 31, 2026 it had revenue of $194000 and net income of -$8M, a net margin of -3985.6%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 13% a year, a 5-year average ROIC of -129%.

About Lexaria Bioscience

Lexaria Bioscience is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $14702 in 2015 to $705923 in 2025, growth of about 47.3% a year. It was profitable in 0 of the last 10 years in our data. It spends 1167% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S48.2
P/B2.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-79.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)52.0%
Revenue growth (5 yrs, per year)12.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2810.7%
ROIC (5-yr avg.)-129.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$194000$705923$464278$86380$255397$722738$384543$222610$433287$63639$40718
Net income-$8M-$12M-$6M-$7M-$7M-$4M-$4M-$4M-$7M-$2M-$1M
Free cash flow-$7M-$10M-$5M-$6M-$5M—-$3M-$4M—-$2M-$663950
EPS (diluted)$-0.34$-0.66$-0.47$-1.01—$-0.95$-1.47$-1.50$-2.70$-0.90$-0.90
Net margin-3985.6%-1686.0%-1248.2%-7715.8%-2846.3%-557.2%-1062.2%-1868.0%-1525.4%-3031.9%-3136.8%
ROIC—-302.9%-55.6%-169.6%-83.3%-33.8%-125.1%-124.0%-276.7%-69.6%-410.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Lexaria Bioscience pay a dividend?

Not currently.

Is Lexaria Bioscience a good stock to buy?

We do not give buy or sell advice. Lexaria Bioscience scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.